Wedbush Assumes Achillion Pharmaceuticals (ACHN) at Outperform; Diverse and Differentiated Pipeline

Wedbush assumes coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $11.00.

Wedbush analyst says, "Our thesis centers on the conviction that Achillion holds a diverse and differentiated pipeline of next-generation candidates for treating Hepatitis C...We believe Achillion is well-positioned for lucrative partnership agreements or an outright acquisition...Our Fair Value of $11 per share represents a compelling risk/reward opportunity, in our opinion."

For more ratings news on Achillion Pharmaceuticals click here and for the rating history of Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $7.64 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Wedbush Starts Immunic Inc. (IMUX) at Outperform
• Goldman Sachs Resumes Luxshare Precision (002475:CH) at Buy